Peter Marks, the former head of vaccine regulation at the FDA, has joined Eli Lilly (LLY) to lead its molecule discovery and infectious disease programs, Lizzy Lawrence of STAT reported. This move is likely to draw criticism over the close ties between federal regulators and the pharmaceutical industry, according to the report. Marks confirmed to STAT that he started his new role at Lilly Research Laboratories on Monday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk (NVO) Cuts Jobs at Key US Site amid Global Restructuring Drive
- Eli Lilly reports final results from LUCENT-3 study of Omvoh
- UNH vs. LLY vs. HIMS: Which Healthcare Stock Is the Best Pick, According to Analysts?
- Eli Lilly & Co: Strong Growth Prospects and Innovation Drive Buy Rating
- Eli Lilly to invest more than $1B in India, Reuters reports